In this manuscript, we thus focus on the following research question: How did the transfer of the new plasmapheresis technologies and the Plasma Mobile impact on the CP donors, the health staff and researchers within the ‘trial communities’ [38] of the Ebola-Tx trial? This evidence concerns the gene CP and Ebola hemorrhagic fever.